Recent clinical trial data underscore the efficacy advantage of combining bepirovirsen with standard nucleoside analogue therapy for hepatitis B management. The combination approach achieved undetectable viral loads in 96% of patients, compared to 78% with standard therapy alone and just 42% in the placebo group during the 48-week study period.
This 18-percentage-point improvement over existing monotherapy represents a meaningful clinical advancement for chronic hepatitis B patients who have historically faced limited functional cure options. The trial also documented a favorable safety profile, with transient liver enzyme elevations occurring in only 8% of combination therapy recipients—a marginal increase over the 3% observed in controls.
These findings validate antisense RNA-targeting technology as a promising therapeutic approach and support the advancement of bepirovirsen toward Phase III evaluation. Read the full article on GMJ Newsroom.
Was this article helpful?
